<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02165657</url>
  </required_header>
  <id_info>
    <org_study_id>06-13-33</org_study_id>
    <secondary_id>06-13-33</secondary_id>
    <nct_id>NCT02165657</nct_id>
  </id_info>
  <brief_title>Excimer Laser, Serum Markers &amp; Psoriasis</brief_title>
  <official_title>Effects of UVB Excimer Laser on Serum Inflammatory Markers in Patients With Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospitals Cleveland Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Photomedex</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospitals Cleveland Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall aims for this study are to determine whether UVB excimer laser treatment of&#xD;
      psoriasis affects serum inflammatory markers, and to assess hyperpigmentation and erythema&#xD;
      with excimer laser treatment.&#xD;
&#xD;
      The investigators hypothesize that treatment of psoriasis with UVB delivered via 308 nm&#xD;
      excimer laser will decrease the levels of serum inflammatory markers. The investigators&#xD;
      hypothesize that treatment will decrease plaque erythema and will result in minimal&#xD;
      hyperpigmentation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will undergo Excimer treatment twice a week until they reach a PASI 75 improvement,&#xD;
      or until they reach the maximum of 20 total treatments. A blood draw to assess serum&#xD;
      inflammatory markers will be performed at the screening visit and final visit. Chromameter&#xD;
      assessment, photographs, PASI and PGA (Physician Global Assessment) will be performed&#xD;
      throughout the study to monitor psoriasis improvement, hyperpigmentation and erythema.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Unable to recruit participants into trial&#xD;
  </why_stopped>
  <start_date>September 2013</start_date>
  <completion_date type="Actual">March 2017</completion_date>
  <primary_completion_date type="Actual">March 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in serum inflammatory markers</measure>
    <time_frame>23 visits (~12 weeks)</time_frame>
    <description>Change in CRP, MPO, S100 and Resistin levels from screening to final visit.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective measure of hyperpigmentation</measure>
    <time_frame>23 visits (~12 weeks)</time_frame>
    <description>Chromameter Assessment to measure hyperpigmentation. L* values are measured with a chromameter. A lower L* means more hyperpigmentation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective measure of erythema</measure>
    <time_frame>23 visits (~12 weeks)</time_frame>
    <description>Chromameter Assessment to measure erythema. a* values are measured with a chromameter. A higher a* means more erythema.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in Psoriasis based on PASI assessment</measure>
    <time_frame>23 visits (~12 weeks)</time_frame>
    <description>PASI will be performed throughout the study to assess response to treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in psoriasis based on PGA</measure>
    <time_frame>23 visits (~12 weeks)</time_frame>
    <description>PGA (Physician Global Assessment) will be performed throughout the study to assess response to treatment.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>Excimer laser</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Excimer laser treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Excimer laser treatment</intervention_name>
    <description>Excimer laser irradiation twice a week for up to 20 treatments.</description>
    <arm_group_label>Excimer laser</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 years and older&#xD;
&#xD;
          -  Male or female with diagnosis of psoriasis&#xD;
&#xD;
          -  Psoriasis involvement of 5-15% BSA&#xD;
&#xD;
          -  Has been off systemic psoriasis therapies (e.g. retinoids, methotrexate, biologic&#xD;
             agents, etc) for at least 4 weeks&#xD;
&#xD;
          -  Has been off topical therapies (e.g. calcipotriene, topical steroids) for at least 2&#xD;
             weeks&#xD;
&#xD;
          -  Fitzpatrick Skin Types I-VI&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Active history of photosensitivity (e.g. xeroderma pigmentosum, lupus erythematosus,&#xD;
             porphyria, severe polymorphous light eruption, solar urticaria)&#xD;
&#xD;
          -  Any suspicion that the psoriasis is of the photosensitive variant.&#xD;
&#xD;
          -  Any medical condition that could be aggravated or may cause extreme discomfort during&#xD;
             the study period.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Margaret Bobonich, NP</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospitals Cleveland Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospitals Cleveland Medical Center (Concord Site)</name>
      <address>
        <city>Concord</city>
        <state>Ohio</state>
        <zip>44077</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 13, 2014</study_first_submitted>
  <study_first_submitted_qc>June 16, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 17, 2014</study_first_posted>
  <last_update_submitted>July 9, 2021</last_update_submitted>
  <last_update_submitted_qc>July 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospitals Cleveland Medical Center</investigator_affiliation>
    <investigator_full_name>Margaret Bobonich, NP</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Excimer laser</keyword>
  <keyword>UVB</keyword>
  <keyword>Psoriasis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 21, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/57/NCT02165657/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

